Since being established more than two decades ago Aurum has expanded to several countries spanning three continents, continuing our successful record of researching, supporting and implementing innovative, integrated approaches to global health.
The sustainability of our global impact succeeds through our inclusive approach where we partner with governments, civil society organisations, the private sector, and communities. Aurum Institute is renowned for its successful research work in gathering evidence and generating reliable data mainly in HIV and TB with resulting interventions that deliver meaningful impact and a deeper understanding of the people and communities we serve.
Unitaid is investing US$59 million in the IMPAACT4TB (Increasing Market and Public health outcomes through scaling up Affordable Access models of short Course preventive therapy for TB) project.
Aurum Institute is spearheading the TB prevention project and will work with the Clinton HIV/AIDS Access Initiative, KNCV Tuberculosis Foundation, John Hopkins University, the Global Drug Facility-Stop TB Partnership, the Treatment Action Group, with support from the World Health Organization, to implement the project in 12 countries in Africa, Latin America and Asia with high burdens of TB or TB/HIV. People living with HIV and child contacts of TB cases less than five years of age will receive a quality-assured, affordable short-course TB preventive therapy consisting of two antibiotics that treat TB (isoniazid and rifapentine) given weekly for three months, known as 3HP.
This study is led and sponsored by the Aurum Institute. The study is a parallel, two-part, open-label, individually randomized, pragmatic trial among HIV-positive individuals. Part A compares a single round of weekly high dose rifapentine plus isoniazid for three months (3HP) to six months of daily isoniazid (6H). Part B compares periodic 3HP (p3HP) to a single round of 3HP.
The location is in South Africa at the Aurum Institute in collaboration with the London School of Hygiene and Tropical Medicine and Johns Hopkins University. The Principal Investigator is Prof Gavin Churchyard, Group CEO at the Aurum Institute.
The purpose of this study is to compare the efficacy and safety of 26 weeks of delamanid (DLM) versus 26 weeks of isoniazid (INH) for preventing confirmed or probable active tuberculosis (TB) during 96 weeks of follow-up among high-risk household contacts (HHCs) of adults with multidrug-resistant tuberculosis (MDR-TB) (index cases). High-risk HHCs are those with HIV or non-HIV immunosuppression, latent TB infection, and young children below the age of 5 years.
The TB Sequel consortium is a research consortium that was built on pre-existing research collaborations within the TTU-TB of the German Center for Infection Research (DZIF) and between LMU and different African Sites (such as the PanACEA-consortium or MaTuTU-project).
The TB-Sequel Network has brought together a number of African partners from countries with a high prevalence of TB and from academic institutions with a track-record in TB research. Each network partner has both the foundation for clinical research as well as specific and complementary areas of expertise.
EHPSA commissioned Aurum Research Institute to assess the policies and practices related to HIV and TB data collection and surveillance in correctional facilities of Malawi, Namibia, Lesotho, Swaziland, and Zambia. It aimed to provide a broad review of two topics: HIV and TB prevention and sexual health services and treatment in correctional facilities; and the collection of routine data collection and surveillance in correctional settings in the region.
The Aurum Institute collaborates with CHAPS and the Bantwana Initiative to increase voluntary medical male circumcision VMMC among adolescent boys and young men ages 10-29 as a mechanism for HIV prevention in Eswatini. VMMC is proven to be effective in preventing new HIV infections, curbing the HIV epidemic.